<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly!

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Esophageal Cancer PDX Models

Esophageal cancer is the 6th most common cause of cancer-related deaths which drives a need for a better understanding of the underlying mechanisms behind the disease through preclinical models. Patient-derived xenograft (PDX) models provide a true representation of human heterogeneity and can be used to better understand these mechanisms in relation to the development of new therapies. Crown Bioscience has a large selection of well-characterized esophageal cancer PDX models, including models with EGFR amplification. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience's HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.

MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
ES0026 Esophageal Cancer ESCC Multiple squamous cell carcinoma of esophagus, well-moderately differentiated, carcinoma in situ, tumor mass: 5cm x 5cm x 2cm, 2cm x 2cm x 1cm, 1.5cm x 1cm x 1cm. CLICK TO VIEW
ES0042 Esophageal Cancer ESCC Moderately-poorly differentiated squamous cell carcinoma CLICK TO VIEW
ES0110 Esophageal Cancer ESCC Squamous cell carcinoma from inferior part of esophagus and gastric cardia, grade II, fungating type, tumor mass: 7.5cm x 4cm x 2cm, infiltrating into serosa. No visible malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/7), left gastric LN (0/6), cardial LN (0/2), LN of lesser curvature (0/8). CLICK TO VIEW
ES0136 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, ulcerative type, poorly differentiated, tumor mass: 5.5cm x 6cm x 1.5cm, infiltrating fibrous membrane. No malignant cells adjacent to both stump. Regional LN: paratracheal LN (0/3), left gastric LN (0/4), carina of trachea LN (0/3), parathoracic duct LN (1/1). CLICK TO VIEW
ES0141 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, ulcerative type, grade II, tumor mass: 7cm x 2.5cm 1.5cm, infiltrating into deep muscular layer. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/3), left gastric LN (0/4), carina of trachea LN (0/3), right superior mediastinum LN (1/1), adjacent to tumor LN (0/1). CLICK TO VIEW
ES0147 Esophageal Cancer ESCC Squamous cell carcinoma of inferior thoracic part of esophagus, medullary type, grade III, tumor mass: 5cm x 4cm x 1.5cm, infiltrating fibrous membranes with massive necrosis. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/12), left gastric LN (0/1). CLICK TO VIEW
ES0148 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type with adeno-differentiation, grade III, tumor mass: 3cm x 2cm x 0.5cm, infiltrating superficial muscular layer.No malignant cells adjacent to superior stump, mild atypical hyperplasia of a little gland in mucosa of inferior stump. Regional LN: paraesophageal LN (0/2), left gastric LN (1/1). CLICK TO VIEW
ES0159 Esophageal Cancer ESCC Squamous cell carcinoma of superior thoracic part of esophagus (postradiotherapy), scirrhous type, grade II, tumor mass: 3.5cm x 1.5cm x 0.5cm. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/3), carina of trachea LN (0/8). CLICK TO VIEW
ES0168 Esophageal Cancer ESCC Squamous cell carcinoma of inferior thoracic part of esophagus, fungating type, grade II-III, tumor mass: 3cm x 2cm x 1cm, invaded superficial muscular layer. No malignant cells adjacent to both stumps. Regional LN: left gastric LN (3/3), paraesophageal LN (0/2). CLICK TO VIEW
ES0172 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade II-III, tumor mass 5cm x 4cm x 1cm, infiltrating into deep muscular layer. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (1/5), left gastric LN (0/1). CLICK TO VIEW
ES0176 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade II, tumor mass: 5cm x 3.5cm x 1cm, infiltrating fibrous membrane. No malignant cells adjacent to both stump. Regional LN: left gastric LN (0/2), paraesophageal LN (2/3), cardia of LN (1/2). CLICK TO VIEW
ES0178 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade II, tumor mass: 3cm X 2.5cm X 1.8cm, infiltrating into fibrous membranes. No malignant cells adjacent to both stump. Regional LN: left gastric LN (2/2), paraesophageal LN (0/1) CLICK TO VIEW
ES0181 Esophageal Cancer Squamous cell carcinoma of inferior thoracic part of esophagus, ulcerative type CLICK TO VIEW
ES0183 Esophageal Cancer EAC Moderately-poorly differentiated adenocarcinoma CLICK TO VIEW
ES0184 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade I-II, tumor mass: 3cm x 2.5cm x 1cm, infiltrating superficial muscular layer. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/4), left gastric LN (0/3), inferior carina of trachea LN (0/7). CLICK TO VIEW
ES0189 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade II, tumor mass: 4cm x 3.5cm x 1cm, infiltrating fibrous membranes. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/5), left gastric LN (0/2), right superior mediastinum LN (3/3). CLICK TO VIEW
ES0190 Esophageal Cancer ESCC Squamous cell carcinoma of superior thoracic part of esophagus, medullary type, grade II, tumor mass: 6cm x 2.5cm x 2cm, infiltrating fibrous membranes. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/5), left gastric LN (0/3), carina of trachea LN (0/3). CLICK TO VIEW
ES0191 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, ulcerative type, grade II, tumor mass 5.5cm x 4.5cm x 0.8cm, infiltrating into fibrous membranes. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/4), left gastric LN (1/1), parathoracic duct LN (0/1). CLICK TO VIEW
ES0195 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, ulcerative type, grade II-III, tumor mass: 4cm x 3.5cm x 0.5cm, infiltrating fibrous membranes and nerve plexus. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/7), left gastric LN (0/3), carina of trachea LN (0/1). CLICK TO VIEW
ES0199 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade III, tumor mass: 4.5cm x 4cm x 1cm, infiltrating into fibrous membranes. No malignant cells adjacent to both stump. Regional LN: left gastric LN (0/1), paraesophageal LN (0/1), inferior lung LN (0/3). CLICK TO VIEW
ES0201 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, medullary type, grade II-III, tumor mass: 4.5cm x 1.5cm x 1cm, infiltrating into fibrous membranes with necrosis. No malignant cells adjacent to both stump. Regional LN: left gastric LN (2/2), carina of trachea LN (0/2). CLICK TO VIEW
ES0204 Esophageal Cancer ESCC Squamous cell carcinoma of inferior thoracic part of esophagus, medullary type, poorly diferentiated, tumor mass 5.5cm x 4.5cm x 1.5cm, infiltrating into deep muscular layer. No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/2), left gastric LN (0/6), carina of trachea LN (0/2), LN of inferior parapulmonary vein (0/2). CLICK TO VIEW
ES0212 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, erosive type, grade II-III, tumor mass: 2.5cm x 2cm x 0.3cm, infiltrating submucosa. No malignant cells adjacent to both stump. Regional LN: paratracheal LN (2/2), paraesophageal LN (0/4), left gastric LN (0/3). CLICK TO VIEW
ES0214 Esophageal Cancer ESCC Squamous cell carcinoma of superior thoracic part of esophagus, nodular type of submucosa, tumor mass 3cm x 2.5cm x 1.5cm, infiltrating into fibrous membranes and severe atypical hyperplasia of squamous epithelium. No malignant cells adjacent to both stump. Regional LN: carina of trachea LN (0/4), paratracheal LN (0/1), paraesophageal LN (1/1), left gastric LN (0/3). IHC results: NM23(-), P53(+). CLICK TO VIEW
ES0215 Esophageal Cancer Sarcoma Carcinosarcoma (moderately differentiated squamous cell carcinoma with leiomyosarcoma) of superior thoracic esophagus, intraluminal type, infiltrating submucosa, tumor mass: 6cm x 3cm x 3cm. No malignant cells adjacent to both stump. Regional LN: left gastric LN (0/8), carina of trachea LN (0/7). IHC results: SMA(+), CD34(-), CD117(-), NSE(-), Vimentin(+). CLICK TO VIEW
ES0218 Esophageal Cancer ESCC Squamous cell carcinoma with adenoid differentiated of middle thoracic part of esophagus, medullary type, grade III, tumor mass: 4cm x 4cm x 1.5cm, infiltrating into fibrous membranes.No malignant cells adjacent to both stump. Regional LN: paraesophageal LN (0/4), left gastric LN (0/1). CLICK TO VIEW
ES0219 Esophageal Cancer ESCC Squamous cell carcinoma of middle thoracic part of esophagus, ulcerative type, grade II-III, tumor mass: 4cm x 3cm x 1cm, infiltrating into fibrous membranes. No malignant cells adjacent to both stump. Regional LN: parapulmonary artery LN (0/2), paraesophageal LN (0/5), left gastric LN (0/5). CLICK TO VIEW
ES0630 Esophageal Cancer ESCC Squamous cell carcinoma invade fibrous membranes. No malignant cells adjacent to both stump. Regional LN: paraesphageal LN (0/3), left gastric LN (0/2), hilum of lung LN (0/3). IHC results: CD117(+), Vim(+), Act(-), S-100(-). CLICK TO VIEW
ES10081 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES10082 Esophageal Cancer NA Invasive, MD adenocarcinoma of gastroesophageal junction CLICK TO VIEW
ES10084 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES10086 Esophageal Cancer NA Poorly differentiated carcinoma CLICK TO VIEW
ES11061 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES11062 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES11063 Esophageal Cancer ADC Esophageal Carcinoma. Gastroesophageal adenocarcinoma. CLICK TO VIEW
ES11065 Esophageal Cancer NA Metastatic adenocarcinoma, predominantly clear cell type. CLICK TO VIEW
ES11068 Esophageal Cancer NA Esophageal Carcinoma. Adenocarcinoma. CLICK TO VIEW
ES11069 Esophageal Cancer NA Esophageal Carcinoma. Invasive adenocarcinoma, PD. CLICK TO VIEW
ES11072 Esophageal Cancer NA Mestastatic large cell neuroendocrine carcinoma. CLICK TO VIEW
ES11073 Esophageal Cancer ADC Esophageal Carcinoma CLICK TO VIEW
ES11074 Esophageal Cancer ADC Esophageal Carcinoma CLICK TO VIEW
ES11075 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES11077 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES11079 Esophageal Cancer NA Esophageal Carcinoma CLICK TO VIEW
ES11082 Esophageal Cancer NA Esophageal Carcinoma. Adenocarcinoma. CLICK TO VIEW
ES11085 Esophageal Cancer NA Esophageal Carcinoma. Metastatic adenocarcinoma. CLICK TO VIEW
ES11086 Esophageal Cancer NA Esophageal carcinoma CLICK TO VIEW
ES11087 Esophageal Cancer NA Esophageal carcinoma. Consistent with adenocarcinoma. CLICK TO VIEW
ES11088 Esophageal Cancer ADC Adenocarcinoma CLICK TO VIEW
ES11091 Esophageal Cancer NA Esophageal carcinoma CLICK TO VIEW
ES16021 Esophageal Cancer NA Mestastatic small cell cancer esophageal. CLICK TO VIEW
ES2116 Esophageal Cancer EAC Adenocarcinoma derived from juncture of stomach and esophagus, protruded type, moderately-poorly differentiated, tumor mass: 4cm x 3.5cm. No malignant cells adjacent to esophageal stump and duodenal stump. Regional LN: right cardial LN (0/1), left cardial LN (5/5), LN of lesser curvature (0/5), inferior pyloric LN (0/4), LN of left gastric artery (3/5). IHC results: CD44(+), Cmet(+), EGFR(-), HER2(2+), Ki-67(+50-75%), MMP7(-), P170(weak +), P27(+>75%), P53(-), TOPOII(+25-50%) CLICK TO VIEW
ES2263 Esophageal Cancer ESCC Squamous cell carcinoma of esophagus, poorly differentiated. Tumor size: 5.5X4X2.5cm. IHC results: CK(+), Ki67(10%-60%), CD56(-), Syn(-), P63(+). Reagional LN: left gastric LN (0/1), inferior carina of trachea LN (1/4). CLICK TO VIEW
ES2267 Esophageal Cancer ESCC Squamous cell carcinoma of esophagus, tumor size: 4.5X4X1.7cm. IHC results: CD117(+), CD34(+), DOG-1(+), CK(-), Vim(+), Ki67(1%), SMA(-). Regional LN: left gastric LN (0/1), left cardial LN (0/5), the 2nd group LN (0/5), paraesophageal LN (0/3), cardial LN (0/2), LN from tracheoesophageal groove (0/4), the 7th group (0/6), the 4th group (0/6). CLICK TO VIEW
ES2311 Esophageal Cancer ESCC Squamous cell carcinoma of esophagus, moderately differentiated. Tumor invaded through esophageal wall. Two of nine lymph nodes involved by metastatic carcinoma (2/9). IHC results: CD44(+), CMet(-), COX2(weak +), EGFR(+), ERCC-1(-), HER2(-), Ki-67(+25-50%), P170(-), P27(weak +), P53(+50-75%), TOPOII(+<25%). CLICK TO VIEW
ES2356 Esophageal Cancer ESCC NA for clinical diagnosis info. CLICK TO VIEW
ES2411 Esophageal Cancer EAC, ESCC Adenocarcinoma, c-Myc amplification CLICK TO VIEW
ES2563 Esophageal Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
ES3431 Esophageal Cancer ESCC Esophagus: squamous cell carcinoma, moderately differentiated CLICK TO VIEW
ES3862 Esophageal Cancer ESCC Moderately differentiated squamous cell carcinoma, all lymph nodes are benign (0/25) CLICK TO VIEW
ES3863 Esophageal Cancer ESCC The middle esophagus: squamous cell carcinoma, moderately to poorly differentiated, invaded the outer membrane of esophagus. One of fourteen lymph nodes involved by metastatic carcinoma (1/14). CLICK TO VIEW
ES3864 Esophageal Cancer NA Esophagus: squamous cell carcinoma, moderately differentiated, invasived to the outer membrane of esophagus, fifteen of fifty-four lymph nodes involved by metastatic carcinoma (15/54) CLICK TO VIEW
ES3865 Esophageal Cancer NA Esophagus: moderately differentiated squamous cell carcinoma. All lymph nodes are benign (0/21). CLICK TO VIEW
ES3867 Esophageal Cancer NA Esophagus: squamous cell carcinoma, poorly differentiated, invasived to submucosa, two of twenty lymph nodes involved by metastatic carcinoma (2/20) CLICK TO VIEW
ES3872 Esophageal Cancer NA Middle esophagus: squamous cell carcinoma, moderately differentiated, one of twenty-nine lymph nodes involved by metastatic carcinoma (1/29) CLICK TO VIEW
ES3879 Esophageal Cancer ESCC N/A CLICK TO VIEW
ES3885 Esophageal Cancer ESCC N/A CLICK TO VIEW
ES3892 Esophageal Cancer NA NA CLICK TO VIEW
ES3894 Esophageal Cancer NA The middle and lower esophagus: squamous cell carcinoma, well to moderately differentiated, invaded deep muscular layer. Four of twenty lymph nodes involved by metastatic carcinoma (4/20). CLICK TO VIEW
ES3903 Esophageal Cancer NA NA CLICK TO VIEW
ES3904 Esophageal Cancer NA NA CLICK TO VIEW
ES3908 Esophageal Cancer NA NA CLICK TO VIEW
ES3910 Esophageal Cancer NA NA CLICK TO VIEW
ES6463 Esophageal Cancer ESCC NA CLICK TO VIEW
ES6470 Esophageal Cancer NA NA for clinical diagnosis info. CLICK TO VIEW
ES6824 Esophageal Cancer ESCC NA for clinical diagnosis info. Pathology QC: Moderately to poorly differentiated squamous cell carcinoma with massive necrosis (Pa, P6) CLICK TO VIEW
ES9291 Esophageal Cancer NA NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login